Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant

References

• Sehn LH, Berry B, Chhanabhai M, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma.. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Arranz R, Conde E, Grande C, Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol 2008;80:227–235.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S, High-dose chemotherapy and autologous bone marrow transplantation comparedwith MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1297.
   PubMed Web of Science ®Google Scholar
• Glass B, Kloess M, Bentz M, Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006;107:3058–3064.
   PubMed Web of Science ®Google Scholar
• Greb A, Bohlius J, Trelle S, High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338–346.
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol–a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025–3030.
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350: 1287–1295.
   PubMed Web of Science ®Google Scholar
• Stewart DA, Bahlis N, Valentine K, Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006;107:4623–4627.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Haioun C, Mounier N, Emile JF, Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009;20:1985–1992.
   PubMed Web of Science ®Google Scholar
• Fagnoni P, Milpied N, Limat S, Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma. Pharmacoeconomics 2009;27:55–68.
   PubMed Web of Science ®Google Scholar
• Mounier N, Haioun C, Cole BF, Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Blood 2000;95:3687–3692.
   PubMed Web of Science ®Google Scholar
• Andrykowski MA, Bishop MM, Hahn EA, Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol 2005;23:599–608.
   PubMed Web of Science ®Google Scholar
• Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood 2009; 114:7–19.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson N, Bjordal K, EORTC QLQ-C30 scoring manual. 2nd edBrussels: EORTC Quality of Life Study Group; 1999.
   Google Scholar
• Osoba D, Rodrigues G, Myles J, Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–144.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Moinpour CM, Pauler DK, Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21:3512–3519.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Joffe S, Kim HT, Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004;104:2194–2200.
   PubMed Web of Science ®Google Scholar
• Witzens-Harig M, Reiz M, Heiss C, Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol 2009;88:51–57.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG, Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777–783.
   PubMed Web of Science ®Google Scholar